CD274 and bladder transitional cell carcinoma: Most of the above studies only examined the relationship between cuproptosis-based models and immune cell infiltrations in BLCA tumors (26, 27, 29, 30), while only in the report by Li et al, 34 BLCA patients treated with Atezolizumab (anti-PD-L1 antibody) were analyzed for their response rate using a 14 cuproptosis-related gene-containing signature (28).